Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: A meta-analysis

European Journal of Vascular and Endovascular Surgery

Volumn 19, Issue 4, 2000, Pages 370-380

  Bernardi, E ^a   Prins, M H ^b   Ten Cate, J W ^b   Prandoni, P ^a   Simioni, P ^a   Andreozzi, G M ^a   Girolami, A ^a   Buller H R ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adjunct treatment; Meta analysis; Peripheral arterial disease; Revascularisation procedure

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; TICLOPIDINE;

ADJUVANT THERAPY; AMPUTATION; ARTERY DISEASE; ARTICLE; BYPASS SURGERY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDARTERECTOMY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVASCULARIZATION;

EID: 0034177302     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejvs.1999.1034     Document Type: Article

References (70)

1. Lancet. 339:1992;900-901.
2. Goldman M., McCollum C. A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoropopliteal grafts. Vasc Surg. 18:1984;217-221.
3. Hertzer N.R. The natural history of peripheral vascular disease. Implications for its management. Circulation. 83 (Suppl. I):1991;I12-I19.
4. Clagett G.P., Krupski W.C. Antithrombotic therapy in peripheral arterial occlusive disease. Chest. 108 (Suppl.):1995;431S-443S.
5. Bergqvist D., Einarsson E., Norgren L., Troeng T. A comprehensive regional vascular registry: how is the population served? In Greenhalgh RM, Hollier LH, eds. The Maintenance of Arterial Reconstruction. London: WB Saunders. 1991;441-454.
6. Brewster D.C., Lasalle A.J., Robinson J.G., Strayhorn E.C., Darling C. Femoro-popliteal graft failures. Arch Surg. 118:1983;1043-1047.
7. Whittemore A.D., Clowes A.W., Couch N.P., Mannick J.A. Secondary femoropopliteal reconstruction. Ann Surg. 193:1981;35-42.
8. Gallino A., Mahler F., Probst P., Nachbur B. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation. 70:1984;619-623.
9. Walker P.M., Imparato A.M., Riles T.S., Mintzer R., Kopelman I. Long-term results in superficial femoral artery endarterectomy. Surgery. 89:1981;23-27.
10. Chan P., Mill S., Mulloy B., Kakkar V., Demeliou-Mason C. Heparin inhibition of human vascular smooth muscle cell hyperplasia. Int Angiol. 11:1992;261-267.
11. Balkau B., Vray M., Eschwege E. Epidemiology of peripheral arterial disease. J Cardiovasc Pharmacol. 23 (Suppl. 3):1994;8S-16S.
12. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106.
13. Weichert W., Meents H., Abt K. Acetylsalicylic acid-reocclusion-prophylaxis after angioplasty (ARPA-Study). Vasa. 23:1994;57-65.
14. Ranke C., Creutzig A., Luska G. Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Investig. 72:1994;673-680.
15. Do D.D., Mahler F. Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology. 193:1994;567-571.
16. Minar E., Ahmadi A., Koppensteiner R. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation. 91:1995;2167-2173.
17. Study Group on Pharmacological Treatment after PTA. Platelet inhibition with ASA/Dipyridamole after Percutaneous Balloon Angioplasty in patients with symptomatic lower limb arterial disease. A prospective double blind trial. Eur J Vasc Surg. 8:1994;83-88.
18. Fontaine V.R., Kim M., Kicny R. Die chirurgische Behandlung der peripheren Durchblutungsstörungen. Helv Chir Acta. 5/6:1954;499-533.
19. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst. 22:1959;719-748.
20. Rao C.R. Linear statistical inference and its applications. John Wiley and Sons eds. 1973;389-391.
21. Kretschmer G., Wenzl E., Schemper M. Vein bypass surgery for femoro popliteal arteriosclerosis: influence of different risk factors on patient survival and the importance of anticoagulant treatment. Eur J Vasc Surg. 2:1988;77-81.
22. Benedetti Valentini F., Irace L., Gattuso R. Arterial repair of the lower limbs: prevention of prosthetic grafts occlusion by LMW-heparin. Int Angiol. 7(Suppl. 3):1988;29-32.
23. Davidovic L.B., Vranes M.R., Lotina S.I. Intraarterial perfusion of prostaglandin EI after lumbar sympathectomy or reconstruction on femoropopliteal segment. Int Angiol. 10:1991;178-181.
24. Lundgren F., Dahllof A.G., Schersten T., Bylund-Fellenius A.C. Muscle enzyme adaptation in patients with peripheral arterial insufficiency: spontaneous adaption, effect of different treatments and consequences on walking performance. Clin Sci. 77:1989;485-493.
25. Donaldson D.R., Kester R.C., Hall T.J. Do antiplatelet-modifying agents influence the patency of femoropopliteal Dacron bypass grafts? Br J Surg. 69:1982;284.
26. Sheehan S.J., Salter M.C.P., Donaldson D.R., Rajah S.M., Kester R.C. Five year follow up of long-term aspirin-dipyridamole in femoropopliteal Dacron bypass grafts. Br J Surg. 74:1987;330.
27. 111indium-platelet deposition predict patency in prosthetic arterial grafts? Br J Surg. 70:1983;635-638.
28. Franks P.J., Sian M., Kenchington G.F., Alexander C.E., Powell J.T., Femoropopliteal Bypass Trial Participants. Aspirin usage and its influence on femoro-popliteal vein graft patency. Eur J Vasc Surg. 6:1992;185-188.
29. Kretschmer G., Wenzl E., Schemper M. Influence of postoperative anticoagulant treatment on patient survival after femÍoropopliteal vein bypass surgery. Lancet. 1:1988;797-798.
30. Kretschmer G., Wenzl E., Piza E. The influence of anticoagulant treatment on the probability of function in femoroÍpopliteal vein bypass surgery: analysis of a clinical series (1970 to 1995) and interim evaluation of a controlled clinical trial. Surgery. 102:1987;453-459.
31. Kretschmer G., Wenzl E., Wagner O. Influence of anticoagulant treatment in preventing raft occlusion following saphenous vein bypass for femoropopliteal occlusive disease. Br J Surg. 73:1986;689-692.
32. Robicsek F., Daugherty H.K., Mullen D.C. The effect of continued cigarette smoking on the patency of synthetic vascular grafts in Leriche syndrome. J Thorac Cardiovasc Surg. 70:1975;107-112.
33. Ameli F.M., Stein M., Provan J.L., Prosser R. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg. 3:1989;20-25.
34. Faulkner K.W., House A.K., Castledon W.M. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 5:1983;217-219.
35. Myers K.A., King R.B., Scott D.F., Johnson N., Morris P.J. The effect of smoking on the late patency of arterial reconstructions in the legs. Br J Surg. 65:1978;267-271.
36. Rosenthal D., Mittenthal M.J., Ruben D.M. The effects of aspirin, dipyridamole and warfarin in femorodistal reconÍstruction; long term results. Am Surg. 53:1987;477-481.
37. Broome A., Davidson T., Eklof B., Hansson L. Effect of platelet aggregation inhibitors on the rate of thrombectomy following arterial reconstructions with Gore-Tex prostheses: a retrospective study. Vasa. 11:1982;210-212.
38. Tetteroo E., Mali W.P., Rienks R., van Kester J.A., Banga J.D. The significance of coumarin anticoagulation in laser assisted percutaneous transluminal angioplasty of femoropopliteal arterial obstructions. Eur J Rad. 19:1995;86-90.
39. Ohtake H., Urayama H., Kimura K. Comparison of cilostazol with warfarin as antithrombotic therapy after femoro-popliteal bypass surgery using an ePTFE graft. Minerva Cardiologica. 45:1997;527-530.
40. Green R.M., Roedersheimer L.R., DeWeese J.A. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery. 92:1982;1016-1026.
41. Kohler T.R., Kaufman J.L., Kacoyanis G. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery. 96:1984;462-466.
42. Donaldson D.R., Salter M.C.P., Kester R.C. The influence of platelet inhibition on the patency of femoropopliteal dacron bypass grafts. Vasc Surg. 19:1985;224-230.
43. McCollum C., Alexander K., Kenchington G., Franks P.J., Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg. 13:1991;150-162.
44. Harjola P.T., Meurala H., Frick M.H. Prevention of early reocclusion by Dipyridamole and ASA in arterial reconstructive surgery. J Cardiovasc Surg. 22:1981;141-145.
45. Clyne C.A.C., Archer T.J., Atuhaire L.K., Chant A.D.B., Webster J.H.H. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg. 74:1987;246-248.
46. Satiani B. A prospective randomized trial of aspirin in femoral popliteal and tibial bypass grafts. Angiology. 36:1985;608-616.
47. Heiss H.W., Just H., Middleton D., Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology. 41:1990;263-269.
48. Lassila R., Lepantalo M., Lindfors O. The effect of acetylÍsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World J Surg. 15:1991;378-382.
49. Castelli P., Basellini A., Agus G.B. Thrombosis prevention with ticlopidine after femoropopliteal thromboendarterectomy. Int Surg. 71:1986;252-255.
50. Becquemin J.P. Effect of ticlopidine on the long-term patency of saphenous-vein bypass graft in the legs. NEJM. 337:1997;1726-1731.
51. Arfvidsson B., Lundgren F., Drott C., Schersten T., Lundholm K. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg. 159:1990;556-560.
52. Kretschmer G., Herbst F., Prager M. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg. 127:1992;1112-1115.
53. Mahler F., Schneider E., Gallino A., Bollinger A. Combination of Suloctidil and anticoagulation in the prevention of reocclusion after femoro-popliteal PTA. Vasa. 16:1987;381-385.
54. Rutherford R.B., Jones D.N., Bergentz S.E. The efficacy of dextran 40 in preventing early postoperative thrombosis following difficult lower extremity bypass. J Vasc Surg. 1:1984;765-773.
55. 1therapy following profundaplasty in patients with severe limb ischaemia. Early and long-term results. Vasa. 26:1997;117-121.
56. Lundgren F., Dahllöf A.G., Lundholm K., Schersten T., Volkmann R. Intermittent claudication - surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency. Ann Surg. 209:1989;346-355.
57. Provan J.L., Sojka S.G., Murnaghan J.J., Jaunkalns R. The effect of cigarette smoking on the long term success rate of aortofemoral and femoropopliteal reconstructions. Surg Gynecol Obstet. 165:1987;49-52.
58. Lassila R., Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand. 154:1988;635-640.
59. Powell J.T., Greenhalgh R.M. Smoking and factors influencing the outcome of arterial reconstruction. Ann Chir Gynaecol. 81:1992;236-241.
60. DAddato M., Curti T., Bertini D. Indobufen vs acetylÍsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology. 11:1992;106-112.
61. 1as an adjuvant therapy in the event of femÍoropopliteal and crural great saphenous vein in situ bypass surgery. Vasa. 17 (Suppl.):1987;23-25.
62. Lucas M.A. Prevention of postoperative thrombosis in peripheral arteriopathies. Pentoxifylline vs. conventional antiaggregants: a six months randomized follow-up study. Angiology. 35:1984;445-450.
63. Raithel D. Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vasc Surg. 21:1987;208-214.
64. Bollinger A., Brunner U. Antiplatelets drugs improve the patency rates after femoro-popliteal endoarterectomy. Vasa. 14:1985;272-279.
65. Edmondson R.A., Cohen A.T., Das S.K., Wagner M.B., Kakkar V.V. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet. 344:1994;914-918.
66. Janzon L., Bergqvist D., Boberg J. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 227:1990;301-308.
67. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 308:1994;159-168.
68. Diener H.C., Cunha L., Forbes C. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 143:1996;1-13.
69. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339.
70. Girolami B., Bernardi E., Prins M.H. Antithrombotic drugs in the primary medical management of intermittent claudication: A meta-analysis. Thromb Haemost. 81:1999;715-722.